Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer.
Owen JS, Rackley RJ, Hummel MA, Roepcke S, Huang H, Liu M, Idris TA, Murugesan SMN, Marwah A, Loganathan S, Ranganna G, Barve A, Waller CF, Socinski MA. Owen JS, et al. Among authors: murugesan smn. Eur J Drug Metab Pharmacokinet. 2023 Nov;48(6):675-689. doi: 10.1007/s13318-023-00855-3. Epub 2023 Oct 4. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37792130 Clinical Trial.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
Andersen G, Singh G, Murugesan SMN, Gogineni R, Sharma N, Panda J, Marwah A, Loganathan S, Athalye SN. Andersen G, et al. Among authors: murugesan smn. Diabetes Obes Metab. 2023 Jun;25(6):1485-1494. doi: 10.1111/dom.14994. Epub 2023 Feb 14. Diabetes Obes Metab. 2023. PMID: 36708333 Clinical Trial.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.
Plum-Mörschel L, Klein O, Singh G, Murugesan SMN, Marwah A, Sharma N, Panda J, Loganathan S, Lakshmi GC, Athalye SN. Plum-Mörschel L, et al. Among authors: murugesan smn. Diabetes Obes Metab. 2022 Sep;24(9):1819-1828. doi: 10.1111/dom.14768. Epub 2022 Jun 6. Diabetes Obes Metab. 2022. PMID: 35589611 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.
Plum-Mörschel L, Singh G, Murugesan SMN, Marwah A, Panda J, Loganathan S, Athalye SN. Plum-Mörschel L, et al. Among authors: murugesan smn. Diabetes Obes Metab. 2022 Apr;24(4):713-721. doi: 10.1111/dom.14635. Epub 2022 Jan 28. Diabetes Obes Metab. 2022. PMID: 34981621 Free PMC article. Clinical Trial.